Baxter raised its full-year 2026 organic sales guidance to +3-4% and reported year-to-date free cash flow of $705 million. It also completed a $600 million cash tender offer that retired $864 million of debt.
BAX · Baxter International Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 48%
- Last earnings
- Oct 29, 2026
- Latest filing
- 10-Q · Oct 29
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Third-quarter global sales rose 5% to approximately $3 billion on both reported and organic bases, and adjusted earnings were $0.58 per diluted share. The company raised its full-year organic sales growth outlook to 3% to 4% from 2% to 3%, and its adjusted earnings per diluted share outlook to $2.05 to $2.15.
Baxter International reported net income attributable to Baxter stockholders of $294 million, or $0.57 per diluted share, for the three months ended September 30, 2026, compared with $(46) million, or $(0.09) per diluted share, a year earlier. Results included a $253 million gain on early extinguishment of debt. The company expects no meaningful Novum LVP sales while shipment and installation holds remain in effect.
Baxter reported third-quarter sales of approximately $2.98 billion, up 5% on both a reported and organic basis, with U.S. GAAP diluted earnings per share of $0.57. The company raised its full-year 2026 reported sales growth outlook to 4% to 5%, from 3% to 4%. The board declared a quarterly cash dividend of $0.01 per share, payable January 4, 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Baxter reported Q2 sales of $2.96B (up 5% reported and organic), beating expectations and driven by broad-based growth including a $75M IEEPA tariff refund not in prior guidance; the company raised full-year 2026 reported sales growth to 3-4%, organic sales to 2-3%, and adjusted EPS to $1.95-$2.15 from $1.85-$2.05.
- + Raised full-year 2026 adjusted EPS guidance to $1.95-$2.15 from $1.85-$2.05, reflecting the Q2 tariff refund
- + Advanced Surgery sales grew 12% to $331M on continued strong global demand for hemostats and sealants
- − Q2 adjusted EPS of $0.56 declined 5% YoY due to higher-cost inventory roll-through and unfavorable prior-year comparison
- − MPT segment adjusted operating margin fell 350 bps to 19.3% on higher manufacturing costs and Section 232 tariff impact
- − Adjusted gross margin contracted 210 bps to 38.6% and adjusted operating margin fell 90 bps to 14.2%
- − Novum IQ LVP remains on shipment and installation hold, pressuring Infusion Systems sales and creating customer uncertainty
- − Supply constraints on injectables from a contract manufacturer and softness in pre-mixed products continue to weigh on results
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Organic sales growth non-GAAP | 5% | Three Months Ended June 30, 2026 filing | — |
| Segment operating income - Healthcare Systems & Technologies | $163M | Three Months Ended June 30, 2026 filing | — |
| Segment operating income - Medical Products & Therapies | $400M | Three Months Ended June 30, 2026 filing | — |
| Special items impact on net income (loss) attributable to Baxter stockholders non-GAAP | $155M | Three Months Ended June 30, 2026 filing | — |
| Special items impact on net income (loss) from continuing operations non-GAAP | $155M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BAX
this stock
Baxter International Inc
|
$13.14B | +32.9% | +5.7% | — | 4.6% |
|
ISRG
Intuitive Surgical Inc
|
$138.33B | -29.5% | +20.5% | 48.4 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$57.96B | — | +8.2% | 94.2 | 3.0% |
|
MDLN
Medline Inc.
|
$48.72B | -11.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.70B | -5.7% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 26
Baxter raised its full-year 2026 organic sales guidance to +3-4% and reported year-to-date free cash flow of $705 million. It also completed a $600 million cash tender offer that retired $864 million of debt.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BAX | -1.6% | +0.4% | +35.9% | +10.4% | +32.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +6.9% | +9.6% | +45.1% | +19.1% | +31.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.